Methenolone (Primobolan): Mild Anabolic Research Profile

Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

Methenolone (1-methyl-5α-dihydrotestosterone) is a synthetic androgen distinguished by two pharmacological properties that make it unique among anabolic research compounds: it is the only injectable AAS with no reports of significant hepatotoxicity despite an A ring modification, and the oral acetate ester achieves bioavailability via a non-C17α-alkylation mechanism, making it the only non-hepatotoxic oral androgen. Available as methenolone enanthate (injectable, t½ ~10 days) and methenolone acetate (oral), it produces mild anabolic effects with very low androgenicity (A:A ratio ~6:1 by some assays — notably lower selectivity than SARMs, but with a different safety profile).

Table of Contents#

1. Structure: 1-Methyl-DHT Chemistry
2. Oral Bioavailability Without C17α-Alkylation
3. Pharmacokinetics
4. AR Binding and Selectivity Profile
5. HPTA Suppression: Unusually Mild
6. Immune System Research
7. Research Protocols
8. Key References

Structure: 1-Methyl-DHT Chemistry#

DHT scaffold:

• Methenolone = 5α-dihydrotestosterone + C1α double bond (Δ1,2) + C1-methyl group
• 5α-saturated A ring → not aromatizable → no E2 production from methenolone
• Not a substrate for 5α-reductase (already 5α-reduced at C4/C5)

The Δ1,2 double bond and C1-methyl:

• Introduce mild electron delocalization through ring A
• Protect the 3-keto group from 3α/3β-HSD reduction (which would inactivate the compound)
• Allow moderate resistance to first-pass liver metabolism WITHOUT requiring C17α-alkylation

Esters:

• Methenolone acetate (C2 ester): oral use — very short ester, cleaved quickly in gut/liver
• Methenolone enanthate (C7 ester): IM injectable → t½ ~10.5 days

Oral Bioavailability Without C17α-Alkylation#

This is methenolone acetate's most pharmacologically interesting property:

Why most oral androgens require C17α-methylation:

• Testosterone → oral → 17β-HSD oxidizes 17β-OH → inactive 17-keto compound before hepatic portal circulation
• C17α-methyl blocks this enzymatic inactivation

How methenolone acetate achieves oral bioavailability differently:

• Methenolone acetate: the acetate ester at C17 position provides TEMPORARY protection — slowly cleaved in the GI tract
• The Δ1,2 double bond reduces 17β-HSD affinity → methenolone is a POORER substrate for 17β-HSD than testosterone
• Result: partial oral bioavailability (~40–50%) WITHOUT C17α-methylation → no intrinsic hepatotoxicity
• Important: this bioavailability is lower than C17α-alkylated compounds (~50–80%) → higher mg doses needed

Liver safety:

• Methenolone acetate: no significant ALT/AST elevation in clinical use (Squibb's Nibal tablets, used in HIV wasting)
• Mechanism: no BSEP inhibition (no C17α-methyl); no reactive CYP-generated metabolites with hepatotoxic potential
• This makes methenolone a useful reference compound in research: provides oral androgen activity with hepatologically "clean" background

Pharmacokinetics#

AR Binding and Selectivity Profile#

AR affinity:

• Methenolone RBA: ~10–30% of DHT in different assays (lower than most anabolic steroids)
• Despite low RBA, still AR-agonist: biological potency depends on receptor occupancy × intrinsic efficacy
• No progestogenic activity
• No ER activity (non-aromatizing)

A:A ratio:

• Hershberger: levator ani / ventral prostate ~6:1 in most assays
• Lower selectivity than SABMs but with a very different safety profile
• Predominantly Type I/II muscle fiber activation; weaker androgenic signal in prostate at equivalent anabolic doses

Unique feature: very mild SHBG binding → minimal SHBG displacement from testosterone → in testosterone co-research protocols, does not significantly alter free testosterone fraction

HPTA Suppression: Unusually Mild#

Methenolone is one of the mildest HPTA-suppressing androgens studied:

Clinical evidence:

• HIV wasting trials (Storer et al.): methenolone at anabolic doses → LH suppression ~30–40% (vs. 60–75% for testosterone at comparable anabolic doses)
• Partial HPTA preservation → useful for research models where some HPTA function must be maintained

Mechanism of mild suppression:

• Low AR affinity at hypothalamus → less AR-mediated GnRH suppression
• Non-aromatizing → no E2-mediated negative feedback via ERα at hypothalamus (E2 feedback is the dominant suppression mechanism for testosterone; methenolone lacks this)
• Result: both the AR pathway and ER pathway of HPTA suppression are weak for methenolone

Research implication: Methenolone is useful as a "mild androgen background" in research protocols where partial testosterone replacement is desired without full HPTA shutdown.

Immune System Research#

A historical research interest in methenolone:

Arnold Schwarzenegger-era observation (1980s): Methenolone was anecdotally noted to improve perceived immune function and recovery. This observation triggered scientific investigation.

Research findings:

• Some T-cell studies (in vitro): moderate concentrations of methenolone → may modulate T-helper cell function
• Anti-HIV wasting use: methenolone acetate was used for HIV/AIDS-associated muscle wasting due to perceived better tolerability and mild immunological profile vs. more potent androgens
• NF-κB pathway: some DHT derivatives modulate NF-κB activity → anti-inflammatory properties (but this is shared across many androgens)

Status: Immune-modulating properties of methenolone are not well-mechanistically characterized; most data is anecdotal or based on clinical observation. Active research question.

Research Protocols#

HPTA suppression comparison (intact rats)#

Non-hepatotoxic oral anabolic comparison: methenolone acetate vs. oxandrolone (liver safety)#

Key References#

1. Storer TW, et al. (2003). "Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension." Journal of Clinical Endocrinology and Metabolism, 88(4):1478–1485.

2. Gao W, et al. (2005). "Selective androgen receptor modulators (SARMs): novel anabolic therapies." Drug Discovery Today, 10(10):719–730.

3. Basaria S. (2010). "Androgen abuse in athletes: detection and consequences." Journal of Clinical Endocrinology and Metabolism, 95(4):1533–1543.

Research Use Only: Methenolone is sold exclusively for in-vitro research and laboratory use. Not for unsupervised use. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Research Protocols & Science